6-Chloro-MDA
Pharmaceutical compound
From Wikipedia, the free encyclopedia
6-Chloro-MDA, also known as 6-chloro-3,4-methylenedioxyamphetamine or as 2-chloro-4,5-methylenedioxyamphetamine (2-Cl-4,5-MDA), is a psychoactive drug of the phenethylamine, amphetamine, and MDxx families related to 3,4-methylenedioxyamphetamine (MDA).[1][2] It is the 6-chloro derivative of MDA.[1] The drug has an active dose of 160 mg orally and a duration of approximately 8 hours.[1] It is a weak monoamine oxidase inhibitor (MAOI).[3][4][5] 6-Chloro-MDA was first described in the scientific literature by 1970.[2][6] The properties of 6-chloro-MDA in humans were described by Daniel Trachsel and colleagues in 2013 via personal communication with P. Rausch in 2009.[1]
Other names6-Cl-MDA; 6-Chloro-3,4-methylenedioxyamphetamine; 2-Chloro-4,5-methylenedioxyamphetamine; 2-Chloro-4,5-MDA; 2-Cl-4,5-MDA; C-MDA; 6CL-MDA
ATC code
- None
| Clinical data | |
|---|---|
| Other names | 6-Cl-MDA; 6-Chloro-3,4-methylenedioxyamphetamine; 2-Chloro-4,5-methylenedioxyamphetamine; 2-Chloro-4,5-MDA; 2-Cl-4,5-MDA; C-MDA; 6CL-MDA |
| Routes of administration | Oral[1] |
| Drug class | Psychoactive drug |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C10H12ClNO2 |
| Molar mass | 213.66 g·mol−1 |
| 3D model (JSmol) | |
| |
| |